Martina Anzaghe1, Stefan Schülke2, Stephan Scheurer3. 1. Product Testing of Immunological Biomedicines, Paul-Ehrlich-Institut, Langen, Germany. 2. Section Molecular Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich Str. 51-59, D-63225, Langen, Germany. 3. Section Molecular Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich Str. 51-59, D-63225, Langen, Germany. Stephan.Scheurer@pei.de.
Abstract
PURPOSE OF REVIEW: Utilization of virus-like particles (VLPs) is considered to improve allergen-specific immunotherapy (AIT). AIT aims at the efficient uptake of the target allergen by antigen-presenting cells (APCs) subsequently inducing adaptive allergen-specific immune responses to induce tolerance. The purpose of this review is to describe the immune-modulating properties of VLPs per se and to summarize the application of VLPs as antigen carriers, preferably for Th2 cytokines or allergens, with and without simultaneous administration of adjuvants in order to modulate allergic immune responses. RECENT FINDINGS: Currently, a broad variety of approaches considering the origin of the VLPs, the choice of the adjuvant and antigen, and the coupling of the antigen are under preclinical investigation. The data provide evidence that VLPs used as carrier for antigens/allergens strongly increase antigen immunogenicity, and might be suitable to prevent allergies. However, systematic studies in mice showing the immunological mechanism and data from clinical studies are scarce.
PURPOSE OF REVIEW: Utilization of virus-like particles (VLPs) is considered to improve allergen-specific immunotherapy (AIT). AIT aims at the efficient uptake of the target allergen by antigen-presenting cells (APCs) subsequently inducing adaptive allergen-specific immune responses to induce tolerance. The purpose of this review is to describe the immune-modulating properties of VLPs per se and to summarize the application of VLPs as antigen carriers, preferably for Th2 cytokines or allergens, with and without simultaneous administration of adjuvants in order to modulate allergic immune responses. RECENT FINDINGS: Currently, a broad variety of approaches considering the origin of the VLPs, the choice of the adjuvant and antigen, and the coupling of the antigen are under preclinical investigation. The data provide evidence that VLPs used as carrier for antigens/allergens strongly increase antigen immunogenicity, and might be suitable to prevent allergies. However, systematic studies in mice showing the immunological mechanism and data from clinical studies are scarce.
Entities:
Keywords:
Allergen carrier; Delivery system; Modular vaccines; Protein transfer vector; Virus-like particles
Authors: Nishant K Jain; Neha Sahni; Ozan S Kumru; Sangeeta B Joshi; David B Volkin; C Russell Middaugh Journal: Adv Drug Deliv Rev Date: 2014-10-24 Impact factor: 15.470
Authors: Nicole Schmitz; Klaus Dietmeier; Monika Bauer; Melanie Maudrich; Stefan Utzinger; Simone Muntwiler; Philippe Saudan; Martin F Bachmann Journal: J Exp Med Date: 2009-08-10 Impact factor: 14.307
Authors: Yanbing Ma; Andrew J Halayko; Sujata Basu; Qingdong Guan; Carolyn R Weiss; Allan G Ma; Kent T HayGlass; Allan B Becker; Richard J Warrington; Zhikang Peng Journal: Am J Respir Cell Mol Biol Date: 2013-05 Impact factor: 6.914
Authors: Yanbing Ma; Kent T HayGlass; Allan B Becker; Yijun Fan; Xi Yang; Sujata Basu; Ganesh Srinivasan; F Estelle R Simons; Andrew J Halayko; Zhikang Peng Journal: Am J Respir Crit Care Med Date: 2007-06-07 Impact factor: 21.405
Authors: Matthew D Heath; Mona O Mohsen; Pieter-Jan de Kam; Thalia L Carreno Velazquez; Simon J Hewings; Matthias F Kramer; Thomas M Kündig; Martin F Bachmann; Murray A Skinner Journal: Front Immunol Date: 2020-11-24 Impact factor: 7.561